Trifluoroacetate reduces plasma lipid levels and the development of atherosclerosis in mice
Wei TangiD, Audrey S. Black, Romana MoenchiD, Katayoon Marzban, Juan A. Raygoza GarayiD, James J. ZhengiD, Louis Patrick ConwayiD, Antônio F. M. PintoiD, Christopher G. ParkeriD, Alan SaghatelianiD, Luke J. LemaniD, M. Reza GhadiriiD
Abstract
Trifluoroacetate (TFA) has been assumed to be an innocuous counterion (to cationic amino acid side chains) present in countless synthetic bioactive peptides and a few FDA-approved therapeutics. We show here that TFA is in fact bioactive and causes dramatic biological effects in multiple strains of mice and cultured human and rat liver cells. In high-fat diet (HFD)-fed low-density lipoprotein receptor-null (LDLr-/-) mice, TFA reduces the levels of plasma cholesterol, triglycerides, and the development of atherosclerotic lesions following either oral or intraperitoneal administration. These physiological effects were observed with TFA alone, or with TFA present as a counterion of a variety of short, unrelated synthetic peptide sequences. Mechanistic investigations including RNA-seq, confocal microscopy, western blotting, metabolomics, proteomics, pharmacokinetics, and biochemical assays indicated that TFA induces peroxisome proliferation by activating peroxisome proliferator-activated receptor (PPAR)-alpha. We confirmed that TFA also caused peroxisome proliferation and downstream phenotypic effects in cultured human and rat liver cells, wild-type C57/Bl mice, and apolipoprotein E-null (apoE-/-) mice, leading to anti-atherosclerotic effects in the latter strain. Given that TFA is a counterion in many peptides employed in early research and development settings, these findings raise the possibility that TFA may be confounding or contributing to phenotypic changes observed in many studies involving peptides. Although our studies suggest that TFA or its analogues might have therapeutic applications, it should be noted that TFA is also a persistent environmental contaminant that is found at high levels in humans relative to other polyfluoroalkyl substances (PFAS), and is a major metabolite following treatment of patients with common inhaled anesthetics, suggesting that the biological effects reported here could have other implications for human health.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Perfluorooctanoic Acid Induces Liver and Serum Dyslipidemia in Humanized PPARα Mice Fed an American Diet
J. J. Schlezinger, T. Hyotylainen, … T. F. Webster·bioRxiv·Apr 3, 2021
- Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet
J. Schlezinger, H. Puckett, … T. Webster·bioRxiv·Jan 30, 2020
- PFOS aggravates atherosclerosis via Bacteroides caecimuris expansion-driven bile acid remodeling and subsequent intestinal FXR-TLR3 signaling cascade
Lu Jiang, S W Huang, … Z. Y. Fang·bioRxiv·Jul 8, 2026
- Investigating the mode of action for liver toxicity and wasting-like responses produced by high dose exposures to longer chain perfluoroacid substances (PFAS) using high throughput transcriptomics
A. Rasim Barutcu, Michael B. Black, Melvin E. Andersen·bioRxiv·Mar 2, 2024
- Platelet-specific TGFβ1 deficiency aggravates atherosclerosis, vascular inflammation, and hypercholesterolemia in mice
- Palmitic acid reduces viability and increases production of reactive oxygen species and respiration in rat tendon-derived cells
S. Konar, C. P. Hedges, … D. S. Musson·bioRxiv·Feb 8, 2023